New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Johnson & Johnson

JNJ

Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

270.19 3.09 +1.16%
Market cap
$650.7B
P/E
40.5×
Fwd P/E FY26e
41.8×
Dividend yield
1.98%
F-score
3/9
ROIC
11.1%
Net debt / EBITDA
0.5×
Payout ratio
0.8×

Where the cash went Q3 FY2026, quarter to Sep 30, 2026

Free cash flow of $6.4B covered $4.2B of dividends and buybacks. Cash fell by $3.5B. What is a cash flow statement?

Free cash flow
$6.4B 82.3% of operating cash flow
Returned to shareholders
$4.2B 66.0% of free cash flow
Debt, net
−$4.4B repaid
Change in cash
−$3.5B over the period
Where the cash went, in billions of dollars
Operating cash flow7.7
Capital expenditures−1.4
Free cash flow6.4
Acquisitions, net−0.1
Into investments, net−0.6
Dividends−3.2
Buybacks, net−1.0
Debt repaid, net−4.4
Other−0.6
Change in cash−3.5
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Operating cash flow$7.3B$2.5B$8.6B$7.7B
Capex−$1.5B−$1.0B−$1.3B−$1.4B
Free cash flow$5.8B$1.5B$7.4B$6.4B

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Net Income
210.00 5,534.00 5,235.00 5,116.00

+8 more quarters

Depreciation & Amortization
2,117.00 1,959.00 2,004.00 2,011.00
Non Cash Items (Other)
126.00 108.00 509.00 (3,419.00)
Accounts Receivable Change
205.00 (1,356.00) (603.00) 396.00
Change in inventories
(150.00) (571.00) (431.00) (46.00)
Change in payables and accrued liability
2,405.00 2,964.00 (3,920.00) 1,266.00
Change in other assets and liabilities
2,807.00 (22.00) (280.00) 1,985.00
Operating Cash Flow
7,720.00 8,616.00 2,514.00 7,309.00
Capital expenditures
(1,366.00) (1,258.00) (1,020.00) (1,525.00)
Net Aquisitions
(89.00) (263.00) — (3,082.00)
Long-Term Investments Change (Net)
(611.00) 4.00 65.00 (24.00)
Other investing activities
(643.00) 407.00 (85.00) 146.00
Investing cash flow
(2,709.00) (1,110.00) (1,040.00) (4,485.00)
Repayment/Issuance of Debt (Net)
(4,358.00) (5,748.00) 7,214.00 2,105.00
Equity Repurchase (Common, Net)
(966.00) 138.00 (2,856.00) (337.00)
Dividends Paid (Total)
(3,227.00) (3,227.00) (3,131.00) (3,131.00)
Other financial activities
18.00 60.00 (697.00) (6.00)
Financing cash flow
(8,533.00) (8,777.00) 530.00 (1,369.00)
Exchange Rate Adjustment
10.00 5.00 (25.00) 23.00
Change in Cash
(3,512.00) (1,266.00) 1,979.00 1,478.00
Beginning Cash
0.00 0.00 19,709.00 0.00
Ending Cash
(3,512.00) (1,266.00) 21,688.00 1,478.00
Stock Based Compensation
357.00 458.00 300.00 309.00
Dividends Paid (Common)
(3,227.00) (3,227.00) (3,131.00) (3,131.00)
Net Cash/Marketcap
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
5,267.00 1,015.00 (5,234.00) 3,601.00
Investments Change (Net)
(611.00) 4.00 65.00 (24.00)
Issuance/Purchase of Shares
(966.00) 138.00 (2,856.00) (337.00)

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 2, 2026